Latest News

Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018

Jan. 2, 2019

Kamada announced today preliminary and unaudited total revenues for the fourth quarter and full-year 2018. Total revenue for the fourth quarter of 2018 is expected to be between $46.7 million and $48.7 million. Total revenue for full-year 2018 is expected to be between $113 million and $115 million.

Kamada announced the extension of an ongoing investigator initiated, proof-of-concept study evaluating the potential benefit of the Company’s liquid Alpha-1 Antitrypsin (AAT) on liver preservation and transplant rejection prevention.

Sep. 5, 2018

Kamada Announces Extension of Collaboration with Massachusetts General Hospital for a Proof-of-Concept Study Evaluating the Potential Benefit of Liquid Alpha-1 Antitrypsin on Liver Preservation Prior to Transplantation.

Upcoming Events

Kamada to participate in J.P. Morgan 37th Annual Healthcare Conference

Jan. 7-10, 2019 / San Francisco, California

The annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industry leaders, emerging fast-growth companies, innovative technology creators, and members of the investment community.

Past Event

Kamada to participate in 60th annual meeting - ASH (American Society of Hematology)

Dec. 1-4, 2018 / San Diego, CA

The 60th ASH Annual Meeting will be held December 1-4, 2018, in San Diego, CA. The goal of the ASH annual meeting is to present the best new scientific research in all areas of hematology.